260 related articles for article (PubMed ID: 32382041)
1. NT5DC2 promotes tumor cell proliferation by stabilizing EGFR in hepatocellular carcinoma.
Li KS; Zhu XD; Liu HD; Zhang SZ; Li XL; Xiao N; Liu XF; Xu B; Lei M; Zhang YY; Shi WK; Cao MQ; Xu YF; Tang ZY; Sun HC
Cell Death Dis; 2020 May; 11(5):335. PubMed ID: 32382041
[TBL] [Abstract][Full Text] [Related]
2. PLAGL2-EGFR-HIF-1/2α Signaling Loop Promotes HCC Progression and Erlotinib Insensitivity.
Hu W; Zheng S; Guo H; Dai B; Ni J; Shi Y; Bian H; Li L; Shen Y; Wu M; Tian Z; Liu G; Hossain MA; Yang H; Wang D; Zhang Q; Yu J; Birnbaumer L; Feng J; Yu D; Yang Y
Hepatology; 2021 Feb; 73(2):674-691. PubMed ID: 32335942
[TBL] [Abstract][Full Text] [Related]
3. PSMD9 promotes the malignant progression of hepatocellular carcinoma by interacting with c-Cbl to activate EGFR signaling and recycling.
Su Y; Meng L; Ge C; Liu Y; Zhang C; Yang Y; Tian W; Tian H
J Exp Clin Cancer Res; 2024 May; 43(1):142. PubMed ID: 38745188
[TBL] [Abstract][Full Text] [Related]
4. NT5DC2 suppression restrains progression towards metastasis of non-small-cell lung cancer through regulation p53 signaling.
Jin X; Liu X; Zhang Z; Xu L
Biochem Biophys Res Commun; 2020 Dec; 533(3):354-361. PubMed ID: 32962856
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of SNX5 predicts poor prognosis and promotes hepatocellular carcinoma progression by modulating the EGFR-ERK1/2 signaling pathway.
Zhou Q; Huang T; Jiang Z; Ge C; Chen X; Zhang L; Zhao F; Zhu M; Chen T; Cui Y; Li H; Yao M; Li J; Tian H
Oncogene; 2020 Mar; 39(10):2140-2155. PubMed ID: 31819169
[TBL] [Abstract][Full Text] [Related]
6. Ecto-5'-nucleotidase (CD73) is a potential target of hepatocellular carcinoma.
Shali S; Yu J; Zhang X; Wang X; Jin Y; Su M; Liao X; Yu J; Zhi X; Zhou P
J Cell Physiol; 2019 Jul; 234(7):10248-10259. PubMed ID: 30417547
[TBL] [Abstract][Full Text] [Related]
7. Choline Kinase α Mediates Interactions Between the Epidermal Growth Factor Receptor and Mechanistic Target of Rapamycin Complex 2 in Hepatocellular Carcinoma Cells to Promote Drug Resistance and Xenograft Tumor Progression.
Lin XM; Hu L; Gu J; Wang RY; Li L; Tang J; Zhang BH; Yan XZ; Zhu YJ; Hu CL; Zhou WP; Li S; Liu JF; Gonzalez FJ; Wu MC; Wang HY; Chen L
Gastroenterology; 2017 Apr; 152(5):1187-1202. PubMed ID: 28065789
[TBL] [Abstract][Full Text] [Related]
8. STEAP3 promotes cancer cell proliferation by facilitating nuclear trafficking of EGFR to enhance RAC1-ERK-STAT3 signaling in hepatocellular carcinoma.
Wang LL; Luo J; He ZH; Liu YQ; Li HG; Xie D; Cai MY
Cell Death Dis; 2021 Nov; 12(11):1052. PubMed ID: 34741044
[TBL] [Abstract][Full Text] [Related]
9. OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism.
Dai W; Xu L; Yu X; Zhang G; Guo H; Liu H; Song G; Weng S; Dong L; Zhu J; Liu T; Guo C; Shen X
J Hepatol; 2020 May; 72(5):909-923. PubMed ID: 31899205
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.
Zhao D; Zhai B; He C; Tan G; Jiang X; Pan S; Dong X; Wei Z; Ma L; Qiao H; Jiang H; Sun X
Cell Signal; 2014 May; 26(5):1030-9. PubMed ID: 24486412
[TBL] [Abstract][Full Text] [Related]
11. NT5DC2 knockdown inhibits colorectal carcinoma progression by repressing metastasis, angiogenesis and tumor-associated macrophage recruitment: A mechanism involving VEGF signaling.
Zhu Z; Hou Q; Guo H
Exp Cell Res; 2020 Dec; 397(1):112311. PubMed ID: 32991874
[TBL] [Abstract][Full Text] [Related]
12. FAM134B induces tumorigenesis and epithelial-to-mesenchymal transition via Akt signaling in hepatocellular carcinoma.
Zhang ZQ; Chen J; Huang WQ; Ning D; Liu QM; Wang C; Zhang L; Ren L; Chu L; Liang HF; Fan HN; Zhang BX; Chen XP
Mol Oncol; 2019 Apr; 13(4):792-810. PubMed ID: 30556279
[TBL] [Abstract][Full Text] [Related]
13. Long non-coding RNA LINC01503 promotes the progression of hepatocellular carcinoma via activating MAPK/ERK pathway.
Wang MR; Fang D; Di MP; Guan JL; Wang G; Liu L; Sheng JQ; Tian DA; Li PY
Int J Med Sci; 2020; 17(9):1224-1234. PubMed ID: 32547318
[No Abstract] [Full Text] [Related]
14. HCRP1 downregulation promotes hepatocellular carcinoma cell migration and invasion through the induction of EGFR activation and epithelial-mesenchymal transition.
Xu J; Zhang X; Wang H; Ge S; Gao T; Song L; Wang X; Li H; Qin Y; Zhang Z
Biomed Pharmacother; 2017 Apr; 88():421-429. PubMed ID: 28122307
[TBL] [Abstract][Full Text] [Related]
15. APLN promotes hepatocellular carcinoma through activating PI3K/Akt pathway and is a druggable target.
Chen H; Wong CC; Liu D; Go MYY; Wu B; Peng S; Kuang M; Wong N; Yu J
Theranostics; 2019; 9(18):5246-5260. PubMed ID: 31410213
[No Abstract] [Full Text] [Related]
16. Ubiquitin-specific protease 2a promotes hepatocellular carcinoma progression via deubiquitination and stabilization of RAB1A.
Xiong B; Huang J; Liu Y; Zou M; Zhao Z; Gong J; Wu X; Qiu C
Cell Oncol (Dordr); 2021 Apr; 44(2):329-343. PubMed ID: 33074477
[TBL] [Abstract][Full Text] [Related]
17. 2-Methoxyestradiol synergizes with Erlotinib to suppress hepatocellular carcinoma by disrupting the PLAGL2-EGFR-HIF-1/2α signaling loop.
Zheng S; Ni J; Li Y; Lu M; Yao Y; Guo H; Jiao M; Jin T; Zhang H; Yuan A; Wang Z; Yang Y; Chen Z; Wu H; Hu W
Pharmacol Res; 2021 Jul; 169():105685. PubMed ID: 34022398
[TBL] [Abstract][Full Text] [Related]
18. The 14-3-3σ protein promotes HCC anoikis resistance by inhibiting EGFR degradation and thereby activating the EGFR-dependent ERK1/2 signaling pathway.
Song J; Liu Y; Liu F; Zhang L; Li G; Yuan C; Yu C; Lu X; Liu Q; Chen X; Liang H; Ding Z; Zhang B
Theranostics; 2021; 11(3):996-1015. PubMed ID: 33391517
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-424-5p acts as a potential biomarker and inhibits proliferation and invasion in hepatocellular carcinoma by targeting TRIM29.
Du H; Xu Q; Xiao S; Wu Z; Gong J; Liu C; Ren G; Wu H
Life Sci; 2019 May; 224():1-11. PubMed ID: 30876939
[TBL] [Abstract][Full Text] [Related]
20. CD317 Activates EGFR by Regulating Its Association with Lipid Rafts.
Zhang G; Li X; Chen Q; Li J; Ruan Q; Chen YH; Yang X; Wan X
Cancer Res; 2019 May; 79(9):2220-2231. PubMed ID: 30890618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
